10-Q: Inspire Medical Systems Reports Strong Q1 Revenue Growth, Navigates Supply Chain Challenges

Inspire Medical Systems saw a 28.2% increase in revenue in the first quarter of 2024, reaching $164 million, while managing ongoing supply chain issues and expanding its market presence.

Summary

• Inspire Medical Systems reported a revenue of $164 million for the first quarter of 2024, a 28.2% increase compared to $127.9 million in the same period of 2023.
• The company's gross profit was $139.3 million, with a gross margin of 84.9%, slightly up from 84.4% in the first quarter of 2023.
• Operating loss for the quarter was $15.2 million, an improvement from the $19.5 million loss in the prior year.
• Net loss for the quarter was $10 million, compared to a net loss of $15.4 million in the first quarter of 2023.
• The company experienced a significant increase in revenue outside the U.S., with a 141.5% increase compared to the same period last year, partially recovering from previous supply chain issues.
• Research and development expenses increased to $28.9 million, while selling, general, and administrative expenses rose to $125.6 million.
• The company's cash, cash equivalents, and available-for-sale debt securities totaled $469.2 million as of March 31, 2024.
• Inspire added 11 new U.S. sales territories and activated 66 new U.S. medical centers during the quarter.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and improved profitability, but also highlights ongoing supply chain challenges and a class action lawsuit. The overall sentiment is positive but tempered by these risks.

Positives

• The company experienced a significant increase in revenue, both in the U.S. and internationally.
• Gross margin improved slightly, indicating better cost management.
• Net loss decreased, showing progress towards profitability.
• The company is expanding its sales reach by adding new territories and medical centers.
• Inspire has a strong cash position, providing financial stability for future growth.

Negatives

• The company continues to face supply chain challenges, particularly in Europe, which have impacted revenue.
• Operating expenses, including research and development and selling, general, and administrative costs, have increased.
• The company is still operating at a net loss, although it has improved compared to the previous year.
• The company is subject to a class action lawsuit, which could result in significant costs and divert management's attention.

Risks

• The company faces competition from other neurostimulation technologies and traditional OSA treatments.
• Supply chain disruptions, particularly in Europe, could continue to impact revenue.
• The company's growth rate may decline as revenues increase to higher levels.
• The company is subject to a class action lawsuit, which could result in significant costs and divert management's attention.
• The company's future success depends on the market acceptance of its Inspire system and its ability to obtain and maintain adequate reimbursement.
• The company is exposed to risks related to changes in global macroeconomic conditions, including inflation and interest rates.

Future Outlook

The company expects to continue to invest in research and development, expand its sales and marketing organization, and refine its direct-to-consumer outreach. They anticipate further capital expenditures in 2024, primarily for additional production equipment and their SleepSync platform. The company believes its existing cash and investments, along with cash flows from operations, will be sufficient to meet its cash needs for at least the next 12 months.

Management Comments

• Management believes that the company's revenue growth was primarily due to increased market penetration in existing centers, expansion into new territories, and increased physician and patient awareness of the Inspire system.
• Management expects research and development expenses to increase in the future as they develop next generation versions of the Inspire system and SleepSync.
• Management anticipates an increase in stock-based compensation expense with grants of stock options, restricted stock units, performance stock units, and shares of common stock purchased pursuant to the employee stock purchase plan.

Industry Context

The medical technology industry is highly competitive, with companies constantly developing new products and methods to treat OSA. Inspire competes with other neurostimulation technologies, invasive surgical options, and oral appliances. The emergence of GLP-1 drugs for weight loss may also impact the OSA treatment landscape, although Inspire believes there could be a benefit to their business as a result of GLP-1s.

Comparison to Industry Standards

• Inspire's revenue growth of 28.2% is strong compared to the broader medical device industry, which typically sees single-digit growth rates.
• The company's gross margin of 84.9% is high, reflecting the premium pricing of its innovative technology.
• While the company is still operating at a loss, the reduction in net loss compared to the previous year indicates progress towards profitability.
• Compared to LivaNova and Nyxoah, Inspire is the only company with an FDA-approved neurostimulation device for OSA in the US, giving it a competitive advantage.
• The company's expansion into new sales territories and medical centers is in line with industry best practices for growth.

Corporate Governance

Legal Proceedings

• Inspire and two of its executive officers were named as defendants in a purported federal securities law class action filed in the United States District Court for the District of Minnesota.
• The plaintiff alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5, which alleged violations relate to certain prior disclosures of Inspire about the effectiveness of a program intended to help certain customers establish independence in seeking prior authorization from payors for our Inspire therapy.
• The plaintiff seeks to represent a class of shareholders who purchased or otherwise acquired Inspire common stock between May 3, 2023 and November 7, 2023.

Related Party Transactions

• In December 2023, Inspire entered into an agreement with an entity controlled by its Chief Executive Officer to share the costs of a corporate suite at a sports and entertainment venue.

Stakeholder Impact

• Shareholders: The company's strong revenue growth and improved profitability are positive for shareholders, but the class action lawsuit and supply chain issues are potential concerns.
• Employees: The company's growth is leading to increased headcount and compensation, which is positive for employees. However, the company's ongoing challenges may create some uncertainty.
• Customers: The company's expansion into new territories and medical centers is positive for customers, as it increases access to the Inspire system.
• Suppliers: The company's reliance on third-party suppliers creates some risk, but the company's growth is also positive for suppliers.
• Creditors: The company's strong cash position is positive for creditors, as it reduces the risk of default.

Next Steps

• The company plans to continue to refine its approach to direct-to-consumer outreach, including increasing attention to digital advertising directed towards qualified patients.
• The company intends to continue to enhance its digital scheduling capability during the remainder of 2024.
• The company plans to continue to make significant investments to build its sales and marketing organization by increasing the number of U.S., European, and Japanese sales representatives.
• The company expects to formally launch its new physician programmer, called the SleepSync programmer, in the U.S. in the second half of 2024.
• The company expects to obtain EU MDR certification in 2024.

Key Dates

Keywords

Inspire Medical Systems, obstructive sleep apnea, neurostimulation, revenue growth, medical technology, supply chain, gross margin, net loss, sales territories, medical centers, international expansion, GLP-1, EU MDR